Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory clinical study of DF-521 in Amyotrophic Lateral Sclerosis (ECSDA3)
jRCTs031180058Completed
- Sponsor
- Tobishi Pharmaceutical
- Start
- Sep 2017
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of recombinant batroxobin in amyotrophic lateral sclerosis (ALS), sponsored by Tobishi Pharmaceutical. Primary endpoint: Change in ALSFRS-R score. Started Sep 2017; status: completed.
02
Drugs
recombinant batroxobin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCTs031180058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180058.